2型糖尿病治疗新理念冉兴无(演讲四）.ppt

* DISCUSSION: Binds to and activates GLP-1 receptors Not degraded by DPP-4, unlike GLP-1 Effect is additive to endogenous GLP-1 Metabolism and metabolites are well understood SLIDE BACKGROUND: See information about hypoglycaemia, nausea, or pancreatitis and the Important Safety Information included in this presentation, and the accompanying full Prescribing Information * * * * DISCUSSION: BYETTA? can be easily added to a patient’s current therapy Initiate the patient with 5 μg BID; then, based on glycaemic response and tolerability, increase to 10 μg BID after 1 month No dose adjustments are necessary based on meal size or exercise No additional glucose monitoring required BYETTA is available in easy-to-use prefilled pens Before first use, BYETTA must be stored refrigerated at 36oF to 46oF (2oC to 8oC) After first use, BYETTA can be kept at a room temperature not to exceed 77oF (25oC) Do not freeze the BYETTA pen SLIDE BACKGROUND: See accompanying Prescribing Information and safety information included in this presentation * * 回顾总结糖尿病治疗领域胰岛素产品走过的历程和取得的业绩，提出未来的希望：新的治疗药物选择——百泌达 * * * * HbA1c 10 years change * * * * * * * 传统的阶梯治疗在一种方案不能控制血糖时，往往比较迟缓的加入下一步治疗，而且此期间的方案过于渐进和保守，这可能使患者的胰岛素治疗时机延迟；多数患者在诊断后十年才开始基础胰岛素的治疗,这些患者长期血糖不达标，大大增加了心血管的并发风险 * * * 1923年胰岛素问世并进入临床使用以前，糖尿病几乎就等于死亡 糖尿病患者平均生存时间仅4.9年,生存是第一要务 胰岛素的发现改变了糖尿病患者的命运也改变了糖尿病学史 * * * 这是Turner博士，他是UKPDS的主要研究者，在糖尿病领域有很大的贡献。他有一句非常重要的评论，即“我们在胰岛素的使用上并没有做到真正的早期应用，使用过程中也不够积极…”,因此，现在各个权威的糖尿病机构都在强调胰岛素治疗的重要性以及治疗新理念 * * * * * * * Tier 1: well-validated core therapies These interventions represent the best established and most effective and cost- effective therapeutic strategy for achieving the target glycemic goals. The tier one algorithm is the preferred route of therapy for most patients with type 2 diabetes. Tier 2: less well-validated therapies In selected clinical settings, this secondtier algorithm may be considered. When hypoglycemia is particularly undesirable , the addition of exenatide or pioglitazone may be con